Developing vaccines to fight cervical cancer caused by HPV variants.
Strategies to Reduce Global Health Disparities in Cervical Cancer
This study is looking at new vaccines to help fight cervical cancer caused by different types of the HPV16 virus, so that patients can get treatments that work better for their specific virus variant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11027718 on NIH RePORTER |
What this research studies
This research focuses on creating innovative immunotherapeutic vaccines specifically targeting cervical cancers linked to different variants of the HPV16 virus. By utilizing advanced models of HPV cervicovaginal carcinoma, the team aims to understand how these variants affect immune responses and cancer progression. The study will explore the unique characteristics of HPV16 variants found in diverse populations, which may influence the effectiveness of existing vaccines. Patients may benefit from tailored treatments that are more effective against their specific HPV variant.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cervical cancer associated with HPV, particularly those with variants of HPV16.
Not a fit: Patients with cervical cancer not associated with HPV or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cervical cancer vaccines that are tailored to different HPV variants, improving outcomes for patients.
How similar studies have performed: Previous research has shown promise in developing HPV-targeted immunotherapies, but this approach focusing on variant-specific responses is relatively novel.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Wu, Tzyy-Choou — Johns Hopkins University
- Study coordinator: Wu, Tzyy-Choou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.